Comprehensive cannabinoid profiling from whole blood by LC-MS/MS. Cannabis therapy monitoring for research.
11 cannabinoids
3–5 working days
This research panel provides quantitative profiling of 11 cannabinoids and metabolites from whole blood, supporting cannabis therapy monitoring and pharmacokinetic research.
Clinical indications include:
11 cannabinoids: CBD, THC, CBG, CBN, CBC, and their primary metabolites.
All 11 cannabinoids are quantified simultaneously by LC-MS/MS from whole blood, with chromatographic separation of isobaric species (CBD/THC) and stable isotope internal standardisation.
From enquiry to results — a straightforward process.
This test is available to healthcare professionals, wellness brands, clinics, and research institutions worldwide. We currently serve partners in:
Whether you need testing services for your patients, white-label kits for your brand, or method transfer to your own laboratory — get in touch to discuss how we can work together.
This panel provides comprehensive profiling of 11 cannabinoids and their metabolites from whole blood by LC-MS/MS. It is designed for clinical research into cannabis-based therapies, covering CBD, THC, CBG, CBN, CBC, and their primary metabolites.
This panel uses venous whole blood for more comprehensive quantification suited to pharmacokinetic research, providing greater sensitivity and precision for measuring cannabinoid concentrations. The DBS CBD panel is a simpler at-home finger-prick test designed for monitoring product efficacy in a clinical wellness context.
A venous blood draw is performed by a healthcare professional into appropriate collection tubes. The whole blood format provides the sample quality required for precise pharmacokinetic measurements in research settings.
Results are typically delivered within 3 to 5 working days from the time your sample arrives at our laboratory. The analysis is performed by LC-MS/MS, providing accurate quantification of all 11 cannabinoid analytes.
The panel supports dose-response studies, bioequivalence testing, pharmacokinetic profiling of cannabis-based medicines, and monitoring of clinical trials involving cannabinoid therapies. It provides the analytical rigour required for research publications and regulatory submissions.
Masdiag's research cannabinoid panel is available worldwide through our partner network. We currently serve researchers, clinical trial organisations, and healthcare professionals in Europe, the United Kingdom, Asia, Australia, New Zealand, and the United States. Contact us to discuss testing services for your research programme.
Whether you need testing services, method transfer, or white-label kit development — we'd love to hear from you.